close

Agreements

Date: 2018-07-10

Type of information: Development agreement

Compound: five mRNA therapeutic programs for rare diseases with high unmet medical need

Company: BioNTech (Germany) Genevant Sciences (USA - MA)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: development - commercialisation

Action mechanism: mRNA

Disease: Rare diseases

Details:

  • • On July 10th, 2018, BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs.
  • The collaboration in rare diseases will combine Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics. Both companies have established GMP-grade manufacturing capabilities and infrastructure.
  • Under the terms of the agreement, Genevant and BioNTech will pursue the co-development and co-commercialization of five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs on a 50/50 basis. The companies aim to initiate clinical development in 2020.

Financial terms:

  • Genevant is eligible to receive significant commercial milestones for the oncology licenses.

Latest news:

Is general: Yes